Callan Capital, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Callan Capital, LLC
- $1.42 Billion
- Q3 2024
A detailed history of Callan Capital, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 363 shares of REGN stock, worth $246,850. This represents 0.03% of its overall portfolio holdings.
Number of Shares
363
Previous 324
12.04%
Holding current value
$246,850
Previous $340,000
12.06%
% of portfolio
0.03%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding REGN
# of Institutions
1,509Shares Held
82.7MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.34 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.74 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.09 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.33 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$2.92 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $72.9B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...